Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MARK activation is dependent on constitutive epidermal growth factor receptor activation

Clinical Cancer Research

Volumn 12, Issue 9, 2006, Pages 2937-2943

  Nicolle, Gaëlle ^a   Daher, Ahmad ^c   Maillé, Pascale ^a   Vermey, Marcel ^d   Loric, Sylvain ^a   Bakkar, Ashraf ^a   Wallerand, Hervé ^e   Vordos, Dimitrios ^b   Vacherot, Francis ^a   De Medina, Sixtina Gil Diez ^a   Abbou, Claude C ^b   Van Der Kwast, Theodore ^f   Thiery, Jean Paul ^g   Radvanyi, François ^g   Chopin, Dominique K ^a,b  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c LEBANESE UNIVERSITY   (Lebanon)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f MOUNT SINAI HOSPITAL   (Canada)

^g CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR GROWTH; UPREGULATION; UROGENITAL TRACT TUMOR; WESTERN BLOTTING;

CELL DIVISION; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; UROLOGIC NEOPLASMS;

EID: 33646732200     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2148     Document Type: Article

References (34)

1. Messing EM, Bubbers JE, Dekernion JB, Fahey JL. Growth stimulating activity produced by human bladder cancer cells. J Urol 1984;132:1230-4.
2. Theodorescu D, Cornil I, Sheehan C, Man MS, Kerbel RS. Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Res 1991;51:4486-91.
3. Daher A, de Boer WI, El-Marjou A, et al. Epidermal growth factor receptor regulates normal urothelial regeneration. Lab Invest 2003;83:1333-41.
4. Daher A, de Boer WI, Le Frere-Belda MA, et al. Growth, differentiation and senescence of normal human urothelium in an organ-like culture. Eur Urol 2004;45:799-805.
5. De Boer WI, Houtsmuller AB, Izadifar V, Muscatelli-Groux B, Van der Kwast TH, Chopin DK. Expression and functions of EGF, FGF and TGFβ-growth-factor family members and their receptors in invasive human transitional-cell- carcinoma cells. Int J Cancer 1997;71:284-91.
6. Dangles V, Femenia F, Laine V, et al. Two- and three-dimensional cell structures govern epidermal growth factor survival function in human bladder carcinoma cell lines. Cancer Res 1997;57:3360-4.
7. el-Marjou A, Delouvee A, Thiery JP, Radvanyi F. Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression. Carcinogenesis 2000;21:2211-8.
8. Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985;1:366-8.
9. Sauter G, Haley J, Chew K, et al. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 1994;57:508-14.
10. Popov Z, Gil-Diez-De-Medina S, Ravery V, et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 2004;22:93-101.
11. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003;284:122-30.
12. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003;46 Suppl:S85-104.
13. Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol 2003;194:13-9.
14. Daneshmand M, Parolin DA, Hirte HW, et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 2003;9:2457-64.
15. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54.
16. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7 Suppl 4:31-9.
17. Cortes-Funes H, Soto Parra H. Extensive experience of disease control with gefitinib and the role of prognostic markers. Br J Cancer 2003;89 Suppl 2:S3-8.
18. Green MR. Targeting targeted therapy. N Engl J Med 2004;350:2191-3.
19. Peterson MG, Tanese N, Pugh BF, Tjian R. Functional domains and upstream activation properties of cloned human TATA binding protein. Science 1990;248:1625-30.
20. Bindels EM, Vermey M, Rebel JM, Zwarthoff EC, Van Der Kwast TH. In vitro modulation of implantation and intraepithelial expansion of bladder tumor cells by epidermal growth factor. Exp Cell Res 1997;235:395-402.
21. Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:2658-63.
22. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
23. Normanno N, Di Maio M, Perrone F, Campiglio M. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more? J Clin Oncol 2004;22: 2035-6; author reply 36-7.
24. Suzuki T, Nakagawa T, Endo H, et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ("Iressa") is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer 2003;42:35-41.
25. Nutt JE, Lazarowicz HP, Mellon JK, Lunec J. Gefitinib ('"Iressa," ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 2004;90:1679-85.
26. Barnes CJ, Bagheri-Yarmand R, Mandal M, et al. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003;2:345-51.
27. Barnes CJ, Kumar R. Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets. Cancer Metastasis Rev 2003;22:301-7.
28. Becker J. Signal transduction inhibitors-a work in progress. Nat Biotechnol 2004;22:15-8.
29. 1 arrest in oral squamous cell carcinoma cell lines. Oral Oncol 2004;40:43-51.
30. Blain SW, Scher HI, Cordon-Cardo C, Koff A. p27 as a target for cancer therapeutics. Cancer Cell 2003;3:111-5.
31. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003;4:425-9.
32. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001;3:245-52.
33. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
34. Nutt JE, Durkan GC, Mellon JK, Lunec J. Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine. BJU Int 2003;91:99-104.